See more : Shenzhen Bioeasy Biotechnology Co., Ltd. (300942.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Hill-Rom Holdings, Inc. (HRC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hill-Rom Holdings, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Patria Latin American Opportunity Acquisition Corp. (PLAOW) Income Statement Analysis – Financial Results
- Bluejay Mining plc (JAY.L) Income Statement Analysis – Financial Results
- Chyunn Environment Corporation (6911.TWO) Income Statement Analysis – Financial Results
- Relevium Technologies Inc. (RLLVF) Income Statement Analysis – Financial Results
- PotNetwork Holdings, Inc. (POTN) Income Statement Analysis – Financial Results
Hill-Rom Holdings, Inc. (HRC)
About Hill-Rom Holdings, Inc.
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000 systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.02B | 2.88B | 2.91B | 2.85B | 2.74B | 2.66B | 1.99B | 1.69B | 1.72B | 1.63B | 1.59B | 1.47B | 1.39B | 1.51B | 2.02B | 1.96B | 1.94B | 1.83B | 2.04B | 1.76B | 2.11B | 2.10B | 2.05B | 2.00B | 1.78B | 1.68B | 1.62B | 1.58B | 1.45B | 1.43B | 1.20B | 1.11B | 1.14B | 884.30M | 724.60M | 641.10M | 507.60M |
| Cost of Revenue | 1.43B | 1.41B | 1.48B | 1.45B | 1.42B | 1.40B | 1.11B | 906.20M | 935.90M | 879.60M | 810.40M | 753.00M | 759.00M | 838.20M | 1.14B | 1.11B | 1.05B | 921.00M | 1.14B | 1.01B | 1.25B | 1.27B | 1.27B | 1.17B | 1.03B | 908.00M | 1.01B | 939.20M | 634.80M | 646.60M | 555.60M | 508.90M | 596.90M | 410.40M | 328.50M | 286.90M | 265.80M |
| Gross Profit | 1.59B | 1.48B | 1.43B | 1.39B | 1.32B | 1.26B | 880.30M | 779.90M | 780.30M | 754.70M | 781.30M | 716.60M | 627.90M | 669.50M | 881.10M | 849.80M | 888.00M | 908.00M | 901.00M | 748.00M | 854.00M | 826.00M | 776.00M | 834.00M | 745.00M | 776.00M | 613.00M | 637.80M | 813.10M | 783.20M | 643.30M | 597.70M | 541.40M | 473.90M | 396.10M | 354.20M | 241.80M |
| Gross Profit Ratio | 52.61% | 51.20% | 49.01% | 48.95% | 48.13% | 47.34% | 44.28% | 46.25% | 45.47% | 46.18% | 49.09% | 48.76% | 45.27% | 44.41% | 43.54% | 43.29% | 45.82% | 49.64% | 44.12% | 42.57% | 40.53% | 39.41% | 37.91% | 41.68% | 41.95% | 46.08% | 37.73% | 40.44% | 56.16% | 54.78% | 53.66% | 54.01% | 47.56% | 53.59% | 54.66% | 55.25% | 47.64% |
| Research & Development | 144.90M | 136.50M | 139.50M | 135.60M | 133.70M | 133.50M | 91.80M | 71.90M | 70.20M | 66.90M | 63.80M | 58.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 941.00M | 891.50M | 876.10M | 853.30M | 664.20M | 548.30M | 549.50M | 496.40M | 502.00M | 474.60M | 0.00 | 543.90M | 604.40M | 529.10M | 604.00M | 582.00M | 573.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 441.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 941.00M | 891.50M | 876.10M | 853.30M | 664.20M | 548.30M | 549.50M | 496.40M | 502.00M | 474.60M | 0.00 | 543.90M | 604.40M | 529.10M | 604.00M | 582.00M | 573.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 441.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 995.60M | 929.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 517.30M | 22.80M | -1.40M | 3.10M | 394.00M | 6.00M | 9.00M | 780.00M | 618.00M | 582.00M | 565.00M | 606.00M | 481.00M | 99.00M | 433.50M | 481.80M | 578.80M | 593.80M | 485.40M | 460.20M | 401.00M | 338.50M | 270.30M | 240.60M | 171.20M |
| Operating Expenses | 1.14B | 1.07B | 1.08B | 1.03B | 1.01B | 986.80M | 756.00M | 620.20M | 619.70M | 563.30M | 565.80M | 532.90M | 517.30M | 566.70M | 603.00M | 532.20M | 998.00M | 588.00M | 582.00M | 780.00M | 618.00M | 582.00M | 565.00M | 606.00M | 481.00M | 540.00M | 433.50M | 481.80M | 578.80M | 593.80M | 485.40M | 460.20M | 401.00M | 338.50M | 270.30M | 240.60M | 171.20M |
| Cost & Expenses | 2.57B | 2.47B | 2.56B | 2.48B | 2.43B | 2.39B | 1.86B | 1.53B | 1.56B | 1.44B | 1.38B | 1.29B | 1.28B | 1.40B | 1.75B | 1.65B | 2.05B | 1.51B | 1.72B | 1.79B | 1.87B | 1.85B | 1.84B | 1.77B | 1.51B | 1.45B | 1.45B | 1.42B | 1.21B | 1.24B | 1.04B | 969.10M | 997.90M | 748.90M | 598.80M | 527.50M | 437.00M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 65.60M | 74.00M | 89.60M | 95.00M | 88.90M | 90.40M | 18.40M | 9.80M | 9.50M | 6.50M | 8.50M | 8.70M | 10.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 185.80M | 178.80M | 194.80M | 196.50M | 210.80M | 209.00M | 118.20M | 106.40M | 116.80M | 111.70M | 103.90M | 99.70M | 100.20M | 112.80M | 107.30M | 108.80M | 114.00M | 108.00M | 75.00M | 71.00M | 100.00M | 89.00M | 98.00M | 149.00M | 102.00M | 99.00M | 127.60M | 97.50M | 112.70M | 115.30M | 95.00M | 94.00M | 81.00M | 68.80M | 54.40M | 49.30M | 28.30M |
| EBITDA | 554.20M | 524.00M | 493.00M | 488.70M | 484.00M | 439.00M | 202.60M | 231.40M | 270.30M | 281.70M | 271.90M | 290.60M | -268.20M | 253.80M | 398.80M | 447.50M | 6.00M | 338.00M | 313.00M | 50.00M | 323.00M | 329.00M | 293.00M | 442.00M | 361.00M | 332.00M | 297.40M | 242.30M | 347.70M | 297.30M | 240.70M | 220.40M | 208.30M | 189.20M | 164.80M | 149.20M | 90.00M |
| EBITDA Ratio | 18.36% | 18.19% | 16.96% | 17.16% | 17.64% | 16.53% | 10.19% | 13.72% | 15.75% | 17.24% | 17.08% | 19.77% | -19.34% | 16.83% | 19.71% | 22.80% | 0.31% | 18.48% | 15.33% | 2.85% | 15.33% | 15.70% | 14.31% | 22.09% | 20.33% | 19.71% | 18.30% | 15.36% | 24.01% | 20.79% | 20.08% | 19.92% | 18.30% | 21.40% | 22.74% | 23.27% | 17.73% |
| Operating Income | 447.60M | 409.20M | 344.50M | 367.10M | 310.80M | 270.20M | 124.30M | 159.70M | 160.60M | 191.40M | 215.50M | 183.70M | 110.60M | 102.80M | 278.10M | 317.60M | -110.00M | 320.00M | 319.00M | -32.00M | 236.00M | 244.00M | 211.00M | 228.00M | 264.00M | 236.00M | 179.50M | 156.10M | 234.30M | 189.40M | 157.90M | 137.50M | 140.40M | 135.40M | 125.80M | 113.60M | 70.60M |
| Operating Income Ratio | 14.83% | 14.20% | 11.85% | 12.89% | 11.33% | 10.18% | 6.25% | 9.47% | 9.36% | 11.71% | 13.54% | 12.50% | 7.97% | 6.82% | 13.74% | 16.18% | -5.68% | 17.50% | 15.62% | -1.82% | 11.20% | 11.64% | 10.31% | 11.39% | 14.86% | 14.01% | 11.05% | 9.90% | 16.18% | 13.25% | 13.17% | 12.43% | 12.33% | 15.31% | 17.36% | 17.72% | 13.91% |
| Total Other Income/Expenses | -144.80M | -138.00M | -135.90M | -169.90M | -127.80M | -131.90M | -59.20M | -44.50M | -16.60M | -27.90M | -55.80M | -800.00K | -489.40M | -10.50M | 13.40M | 21.40M | -6.00M | -12.00M | -37.00M | -3.00M | -13.00M | -4.00M | -16.00M | 65.00M | -5.00M | -3.00M | -9.70M | -11.30M | -12.70M | -18.10M | -12.20M | -11.10M | -13.10M | -15.00M | -15.40M | -13.70M | -8.90M |
| Income Before Tax | 302.80M | 271.20M | 208.60M | 197.20M | 183.00M | 138.30M | 65.10M | 115.20M | 144.00M | 163.50M | 159.70M | 182.90M | -378.80M | 92.30M | 291.50M | 339.00M | -116.00M | 308.00M | 282.00M | -35.00M | 223.00M | 240.00M | 195.00M | 293.00M | 259.00M | 233.00M | 169.80M | 144.80M | 221.60M | 171.30M | 145.70M | 126.40M | 127.30M | 120.40M | 110.40M | 99.90M | 61.70M |
| Income Before Tax Ratio | 10.03% | 9.41% | 7.18% | 6.92% | 6.67% | 5.21% | 3.27% | 6.83% | 8.39% | 10.00% | 10.03% | 12.45% | -27.31% | 6.12% | 14.40% | 17.27% | -5.99% | 16.84% | 13.81% | -1.99% | 10.58% | 11.45% | 9.53% | 14.64% | 14.58% | 13.84% | 10.45% | 9.18% | 15.30% | 11.98% | 12.15% | 11.42% | 11.18% | 13.62% | 15.24% | 15.58% | 12.16% |
| Income Tax Expense | 54.30M | 48.20M | 56.40M | -55.20M | 50.70M | 15.50M | 18.30M | 54.60M | 39.00M | 42.70M | 26.20M | 56.90M | 26.20M | 25.20M | 100.90M | 117.50M | -20.00M | 120.00M | 100.00M | -25.00M | 53.00M | 86.00M | 71.00M | 109.00M | 102.00M | 93.00M | 79.90M | 55.30M | 89.10M | 65.80M | 56.50M | 50.70M | 52.30M | 50.70M | 53.00M | 49.40M | 28.90M |
| Net Income | 248.50M | 223.00M | 152.20M | 252.40M | 133.60M | 124.10M | 47.70M | 60.60M | 105.00M | 120.80M | 133.30M | 125.30M | -405.00M | 115.80M | 190.60M | 221.20M | -94.00M | 110.00M | 138.00M | -10.00M | 170.00M | 154.00M | 124.00M | 184.00M | 157.00M | 140.00M | 89.90M | 89.50M | 145.90M | 116.20M | 89.20M | 75.70M | 75.00M | 69.70M | 57.40M | 50.50M | 32.80M |
| Net Income Ratio | 8.23% | 7.74% | 5.24% | 8.86% | 4.87% | 4.67% | 2.40% | 3.59% | 6.12% | 7.39% | 8.37% | 8.53% | -29.20% | 7.68% | 9.42% | 11.27% | -4.85% | 6.01% | 6.76% | -0.57% | 8.07% | 7.35% | 6.06% | 9.20% | 8.84% | 8.31% | 5.53% | 5.68% | 10.08% | 8.13% | 7.44% | 6.84% | 6.59% | 7.88% | 7.92% | 7.88% | 6.46% |
| EPS | 3.72 | 3.32 | 2.25 | 3.73 | 2.03 | 1.89 | 0.73 | 1.06 | 1.79 | 1.99 | 2.16 | 2.00 | -6.47 | 1.85 | 3.08 | 3.60 | -1.52 | 1.77 | 2.22 | -0.16 | 2.71 | 2.45 | 1.87 | 2.72 | 2.28 | 2.02 | 1.27 | 1.26 | 2.04 | 1.62 | 1.23 | 1.03 | 1.01 | 0.93 | 0.76 | 0.66 | 0.42 |
| EPS Diluted | 3.72 | 3.32 | 2.25 | 3.73 | 1.99 | 1.86 | 0.73 | 1.04 | 1.74 | 1.94 | 2.09 | 1.97 | -6.47 | 1.85 | 3.07 | 3.59 | -1.52 | 1.75 | 2.22 | -0.16 | 2.71 | 2.45 | 1.87 | 2.72 | 2.28 | 2.01 | 1.27 | 1.26 | 2.04 | 1.62 | 1.23 | 1.03 | 1.01 | 0.93 | 0.76 | 0.66 | 0.42 |
| Weighted Avg Shares Out | 66.85M | 67.21M | 67.66M | 67.61M | 65.81M | 65.71M | 65.17M | 57.44M | 58.52M | 60.80M | 61.69M | 62.79M | 62.57M | 62.43M | 61.82M | 61.45M | 61.77M | 62.24M | 62.03M | 62.70M | 62.80M | 62.90M | 66.30M | 67.60M | 68.80M | 69.47M | 70.80M | 71.30M | 71.52M | 71.73M | 72.66M | 73.22M | 74.23M | 74.59M | 75.54M | 77.10M | 77.75M |
| Weighted Avg Shares Out (Dil) | 66.85M | 67.21M | 67.66M | 67.61M | 67.23M | 66.60M | 65.17M | 58.52M | 60.25M | 62.36M | 63.90M | 63.74M | 62.58M | 62.62M | 62.12M | 61.58M | 61.77M | 62.73M | 62.18M | 62.70M | 62.80M | 62.90M | 66.30M | 67.60M | 68.80M | 69.66M | 70.80M | 71.30M | 71.52M | 71.73M | 72.66M | 73.22M | 74.23M | 74.59M | 75.54M | 77.10M | 77.75M |
Hillrom Reports Fiscal Fourth Quarter and Full-Year 2020 Financial Results
CHICAGO, Nov. 6, 2020 /PRNewswire/ -- Hillrom (NYSE: HRC) today announced financial results for its fiscal fourth quarter and full year ended September 30, 2020, and provided financial guidance for fiscal 2021. For fiscal 2020, Hillrom reported GAAP earnings of...
Global Holter Monitor Market will Showcase Positive Impact During 2020-2024 | Increasing Prevalence of Cardiac Disorders to Boost Market Growth | Technavio
The Global Holter Monitor Market will grow by USD 176.83 mn during 2020-2024
Global Smart Hospitals Market to Surpass US$ 103.6 Billion by 2027, Says Coherent Market Insights (CMI)
North America is expected to hold a dominant position in the global smart hospitals market during the forecast 2020-2027.
Dividend Champion And Contender Highlights: Week Of September 13
A weekly summary of dividend activity for Dividend Champions and Contenders. Companies which changed their dividends.
Analysts Set Hill-Rom Holdings, Inc. (NYSE:HRC) Price Target at $124.00
Hill-Rom Holdings, Inc. (NYSE:HRC) has been assigned an average rating of “Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have given a...
COVID-19 Pandemic Impact on Global Echocardiography Devices Market 2020-2024 | Technavio
The Global Echocardiography (ECG) Devices Market will grow by USD 1.89 bn during 2020-2024
Hill-Rom (NYSE:HRC) PT Lowered to $112.00 at Morgan Stanley
Hill-Rom (NYSE:HRC) had its price objective reduced by Morgan Stanley from $123.00 to $112.00 in a research note released on Monday, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the medical technology company’s stock. A number of other...
Source: https://incomestatements.info
Category: Stock Reports